Pfizer Shot Remains More Than 91% Effective After Six Months
- Pfizer, BioNTech release follow-up data from phase 3 trial
- Covid vaccination stopped almost all cases of severe illness
This article is for subscribers only.
The Pfizer Inc.-BioNTech SE vaccine remained highly effective against Covid-19 after six months, according to new long-term results that Pfizer said could be used to seek an expansion of the shot’s regulatory status.
Follow-up data from a final-stage trial of 46,307 people showed the vaccine was 91.3% effective in preventing symptomatic cases starting one week after the second dose through as long as six months. In the U.S. alone, the efficacy rate was 92.6%, according to a report Thursday by the two companies.